Newsroom | 8909 results

SAN FRANCISCO--(BUSINESS WIRE)--On the occasion of the 44th J.P. Morgan Healthcare Conference in San Francisco, Bayer AG today unveiled the strategic focus for its Pharmaceuticals Division in 2026. Capitalizing on new launch momentum, the company will drive significant global regulatory expansions and market penetration across its pharmaceutical portfolio. High-value commercial products and an accelerating modality-rich pipeline across oncology, cardiology, neurology, and immunology have firmly...

CAMBRIDGE, England & EDINBURGH, Scotland--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and disease research, today announced that it has secured $2.8 million (£2.1 million) in funding. The investment was led by US life sciences specialist BroadOak Capital Partners, with the company’s founding investor, the Roslin Foundation, also participating. The funding will accelerate Axol’s next phase of growth, sup...

IRVING, Texas--(BUSINESS WIRE)--The expanded collaboration enhances AdventHealth’s access to Vizient’s robust data and digital offerings....

ROCHDALE, United Kingdom--(BUSINESS WIRE)--Astoriom today announced the appointment of Will Edwards, MBA as CEO to support global scale-up of sample management operations....

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a milestone year marked by record growth in its provider footprint, profitability across its healthcare business, the launch of Viz Oncology and Viz Assist, and the doubling of its life sciences business over the past 18 months. Viz.ai is now adopted in nearly 2,000 hospitals across the United States, including the majority of the 50 largest health systems, suppo...

MENLO PARK, Calif.--(BUSINESS WIRE)--Inquis Medical, Inc., a privately held medical technology company dedicated to advancing mechanical thrombectomy for venous thromboembolic disease (“VTE”), today announced the closing of a $75 million Series C financing round. The investment, provided by an undisclosed strategic investor, will be used to accelerate nationwide commercial expansion of the AVENTUS™ Thrombectomy System and advance the company’s next-generation product pipeline. The financing fol...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2025 and provided 2026 financial guidance. Preliminary, unaudited revenue for fourth quarter 2025 is expected to be $140.5 million, reflecting growth of approximately 13% over the fourth quar...

MENLO PARK, Calif.--(BUSINESS WIRE)--Seasoned legal leader joins digital heart health company during period of significant growth....

IRVING, Texas--(BUSINESS WIRE)--This program celebrates those who drive innovation, efficiency and excellence across the healthcare industry....

CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that the LifeVest® wearable cardioverter defibrillator (WCD) saved 143 patients between Thanksgiving Day (U.S.) and New Year’s Day, an average of four patients per day. LifeVest is a wearable cardioverter defibrillator (WCD) that is prescribed to heart patients who are at temporary risk of sudden cardiac death due to certain rapid life-threatening heart r...